通过向microRNA-205-5p/Sirtuin 5轴,CircARF3可以缓解过敏性鼻炎
Jing Zheng1, Xi Chen1, Jia-Bin Zhan1
1Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China.
International archives of allergy and immunology
|June 21, 2023
概括
循环RNA ADP-ribosylation factor 3 (circARF3) 通过抑制亡和炎症来缓解过敏性鼻炎. 这项研究表明,circARF3通过miR-205-5p/SIRT5通路作用,减少鼻炎和细胞死亡.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 循环RNAs (circRNAs) 在过敏性鼻炎 (AR) 的发展中发挥着关键作用.
- 了解circRNAs在AR病变发生中的特定功能对于开发向疗法至关重要.
- circRNA ADP-ribosylation factor 3 (circARF3) 已被涉及到AR,但其精确的作用需要详细的研究.
研究的目的:
- 阐明circARF3在过敏性鼻炎 (AR) 发病过程中的作用和机制.
- 在AR中调查涉及circARF3,miR-205-5p和SIRT5的调控网络.
- 在AR模型中评估circARF3的治疗潜力.
主要方法:
- 已建立的AR动物模型使用室内灰尘虫 (HDM) 和体外模型用IL-4/IL-13治疗的鼻上皮细胞 (NEpC).
- 通过使用qRT-PCR,西方斑点和桑格测序验证了circARF3结构和circARF3,miR-205-5p和SIRT5的量化水平.
- 使用 luciferase 记者,RNA 免疫沉降和拉下测试研究了调控相互作用;通过流细胞计,TUNEL 和 ELISA 评估了细胞亡和炎症.
主要成果:
- 在AR模型中,circARF3和SIRT5水平下降,而miR-205-5p在AR模型中增加.
- 通过抑制miR-205-5p,circARF3过度表达减少了NEpC中的亡和炎症.
- 提升SIRT5调节减轻了炎症,其敲击效应被miR-205-5p沉默逆转.
- 在接受HDM治疗的小鼠中,circARF3过度表达改善了组织学损伤,亡和炎症.
结论:
- 在AR中,circARF3功能是抑制细胞灭亡和炎症的抑制剂.
- circARF3的保护作用通过miR-205-5p/SIRT5轴进行介导.
- circARF3有可能成为过敏性鼻炎的治疗点.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
357
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357
01:19Antiasthma Drugs: Leukotriene Modifiers
372
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
372
01:20Asthma: Pathogenesis and Management
461
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
461
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
315
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
315
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
350
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
350
01:17Drugs Used in Lower Respiratory Disorders: Overview
506
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
506